K2 HealthVentures

K2 HealthVentures provides structured debt, royalty financing and growth equity to growth-stage life sciences companies. The firm targets capital-intensive clinical-stage biotechs that need non-dilutive funding to bridge toward commercial milestones or public-market exits. Its structures are customized to company-specific catalysts, including FDA approval timelines and partnership milestones.

K2 operates more as a crossover credit platform than a pure equity VC. It underwrites debt and royalty deals against clinical and regulatory milestones, allowing companies to raise capital with less equity dilution. The firm also maintains a public-company financing practice, enabling it to continue supporting portfolio companies after they go public, which is rare for traditional venture funds.

No. K2 maintains an active practice financing publicly traded life sciences companies. According to public filings, the firm has taken positions in Nasdaq-listed biotechs including Kiniksa Pharmaceuticals and Verona Pharma. This dual private-public capability is a structural differentiator from most venture-stage healthcare investors.

The firm is led by Founder and Managing Partner Parag Shah and Managing Partner Anupam Mishra. Both have shaped the firm's hybrid approach that blends structured credit underwriting with deep domain expertise in clinical-stage biopharma. The firm operates from its primary base in Palo Alto with additional offices in Boston, New York, London and Shanghai.

K2 targets growth-stage life sciences companies at or near clinical and regulatory inflection points — typically firms with later-stage clinical programs, recent FDA approvals, or major pharma partnerships. The firm seeks companies that are too mature for early-stage venture capital but not yet well-covered by public-market institutional lenders.